Nektar Therapeutics (NKTR)

41.69
0.93 2.18
NASDAQ : Health Technology
Prev Close 42.62
Open 43.15
Day Low/High 40.04 / 43.30
52 Wk Low/High 29.22 / 111.36
Volume 2.89M
Avg Volume 1.90M
Exchange NASDAQ
Shares Outstanding 173.09M
Market Cap 7.38B
EPS -0.60
P/E Ratio 10.32
Div & Yield N.A. (N.A)
A Buysider's Preview of Biotech's Biggest Conference

A Buysider's Preview of Biotech's Biggest Conference

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

AstraZeneca, Nektar Opioid Constipation Drug May Have Failed Phase III Study

AstraZeneca, Nektar Opioid Constipation Drug May Have Failed Phase III Study

Nektar and partner AstraZeneca added data to a naloxegol study that could have improperly changed results.

FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs

FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs

Drugs from Salix Pharma, Nektar Therapeutics and Cubist Pharma may be forced into long delays by FDA's request for heart-safety data.

21 Most Volatile Biopharma Stocks Closing Out 2012

21 Most Volatile Biopharma Stocks Closing Out 2012

These biopharma firms will be announcing FDA drug approval decisions and important clinical trial results.

5 Biotech Stocks Poised for Breakouts

5 Biotech Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Nektar Therapeutics Is a Short

Nektar Therapeutics Is a Short

Investor Martin Shkreli believes Nektar's constipation drug is a bust and the stock is a good short.

5 Stocks Poised for Big Breakouts

5 Stocks Poised for Big Breakouts

These stocks look ready to break out and trade higher from current levels.

Nektar Therapeutics' CEO Discusses Q2 2012 Results - Earnings Transcript

Nektar Therapeutics' CEO Discusses Q2 2012 Results - Earnings Transcript

Nektar Therapeutics' CEO Discusses Q2 2012 Results - Earnings Transcript

Disappointment Sinks In

The market is rolling over following initial confusion over the Supreme Court's Obamacare decision.

22 Biopharma Stocks With Breakout Potential in 2012

22 Biopharma Stocks With Breakout Potential in 2012

TheStreet's Adam Feuerstein has compiled a list of drugs with crucial, stock-moving clinical trial catalysts for the remainder of 2012.

Signs Point to MAP Pharma Drug Rejection

Signs Point to MAP Pharma Drug Rejection

FDA regulators have likely derailed MAP Pharma's plans to market an inhaled migraine drug known as Levadex.

Time to Go Short

Time to Go Short

There's been an important change in the last two days, emphasized by a jump in volume to the downside.

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Wednesday as it is currently trading at $4.28, below its previous 52-week low of $4.30 with 372,504 shares traded as of 12:16 p.m. ET. Average volume has been 1.2 million shares over the past 30 days.

Nektar Bulls Fight Through Pain

Nektar Bulls Fight Through Pain

Nektar Therapeutics has some potentially high-value drugs in its pipeline, and bullish option traders are stepping in.

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Monday as it is currently trading at $4.79, below its previous 52-week low of $4.81 with 32,185 shares traded as of 9:51 a.m. ET. Average volume has been 1.3 million shares over the past 30 days.

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Wednesday as it is currently trading at $5.89, below its previous 52-week low of $5.95 with 451,533 shares traded as of 10:23 a.m. ET. Average volume has been one million shares over the past 30 days.

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Tuesday as it is currently trading at $7.05, below its previous 52-week low of $7.08 with 56,271 shares traded as of 9:53 a.m. ET. Average volume has been 958,400 shares over the past 30 days.

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Friday as it is currently trading at $7.37, below its previous 52-week low of $7.38 with 353,832 shares traded as of 2:31 p.m. ET. Average volume has been 990,700 shares over the past 30 days.

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Tuesday as it is currently trading at $7.53, below its previous 52-week high of $16.06 with 2.8 million shares traded as of 3:32 p.m. ET. Average volume has been 945,200 shares over the past 30 days.

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Monday as it is currently trading at $8.32, below its previous 52-week high of $16.06 with 1.1 million shares traded as of 2:53 p.m. ET. Average volume has been 909,200 shares over the past 30 days.

ASCO Conference Blog Recap

ASCO Conference Blog Recap

Adam Feuerstein reports from the American Society of Clinical Oncology (ASCO) annual meeting, where investors are focused on cancer drug stocks.

ASCO '11: Exelixis Drug Shrinks Ovarian Cancer

ASCO '11: Exelixis Drug Shrinks Ovarian Cancer

Exelixis' experimental drug cabozantinib shows activity in ovarian cancer, a preview of expected data in prostate cancer.

ASCO '11: Roche, Avastin and Ovarian Cancer

ASCO '11: Roche, Avastin and Ovarian Cancer

Roche hopes new Avastin data in ovarian cancer presented at the ASCO meeting will convince regulators to approve the drug in Europe and the U.S.

Cancer Stocks Focus of ASCO Abstract Release

Cancer Stocks Focus of ASCO Abstract Release

Ariad Pharmaceutical, Incyte and Exelixis are a few of the biotech companies with important cancer drug data released Wednesday ahead of the ASCO annual meeting.

10 Health Care Stocks With Upside: Analysts

10 Health Care Stocks With Upside: Analysts

Gentium, Concord Medical and ShangPharma are stocks that could deliver up to 72% as per consensus estimates.

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Monday as it changed hands at $8.54 compared with its previous 52-week low of $8.55. Nektar is currently trading at $8.55 with 520,531 shares changing hands as of 3:27 p.m. as compared to the average daily trading volume of 1.2 million.

10 Mid-Caps With Upside: Analysts

10 Mid-Caps With Upside: Analysts

Analysts expect these stocks to outperform their peers and broader markets.

Nektar Therapeutics Inc. Stock Downgraded By TheStreet Ratings (NKTR)

Nektar Therapeutics Inc. Stock Downgraded By TheStreet Ratings (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) has been downgraded by TheStreet Ratings from from a hold to sell.

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Thursday as it changed hands at $9.59 compared with its previous 52-week low of $9.75. Nektar is currently trading at $9.74 with 226,122 shares changing hands as of 11:02 a.m. as compared to the average daily trading volume of 1.1 million.

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Wednesday as it changed hands at $10.34 compared with its previous 52-week low of $10.38. Nektar is currently trading at $10.34 with 274,464 shares changing hands as of 10:32 a.m. as compared to the average daily trading volume of 1.1 million.

TheStreet Quant Rating: D+ (Sell)